Physician profile
Dalia Hammoud
NPI 1528214798
$2,741.95
in general payments reported to CMS, 2019-2025
25 companies · $1,268 in 2025
The $1,268 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $226 · 2024: $1,249 · 2025: $1,268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,551 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,550.60 |
| Education | $191.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $307.16 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $281.69 | 2024-2025 | Lynparza, Calquence, Enhertu |
| Aveo Pharmaceuticals, INC. | $195.59 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $192.46 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $178.81 | 2024-2025 | |
| Astellas Pharma US INC | $176.99 | 2024-2025 | Xtandi, Xospata, Padcev |
| Eisai INC. | $167.64 | 2023-2025 | |
| Janssen Biotech, INC. | $160.52 | 2023-2025 | Erleada, Balversa, Rybrevant |
| Lilly USA, LLC | $143.26 | 2024 | Jaypirca, Retevmo |
| Dendreon Pharmaceuticals LLC | $130.79 | 2024-2025 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $117.29 | 2024-2025 | |
| Exelixis INC. | $103.46 | 2025 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $95.68 | 2023-2025 | Opdivo |
| Regeneron Healthcare Solutions, INC. | $78.31 | 2023-2025 | Libtayo |
| Glaxosmithkline, LLC. | $69.72 | 2024-2025 | Jemperli, Zejula |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $62.73 | 2024-2025 | Xt Cdx |
| Celgene Corporation | $57.93 | 2023-2025 | Reblozyl, Opdualag |
| Gilead Sciences, INC. | $52.74 | 2024-2025 | Trodelvy |
| Alexion Pharmaceuticals, INC. | $42.99 | 2025 | Ultomiris |
| Stemline Therapeutics INC. | $24.83 | 2025 | Orserdu |
| Kite Pharma, INC. | $24.36 | 2025 | Yescarta |
| Genentech USA, INC. | $20.99 | 2025 | Phesgo |
| Pharmacosmos Therapeutics INC. | $20.01 | 2024 | Monoferric |
| Takeda Pharmaceuticals U.S.A., INC. | $18.32 | 2024 | Iclusig |
| Incyte Corporation | $17.68 | 2025 | Jakafi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dalia Hammoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.